Table 1.
Clinical and endocrinological data of the nine IGHD patients
| Patient | Height SD | GH | T4 | PRL | GH treatment | MRI |
|---|---|---|---|---|---|---|
| I.2 | −3.2 | Not eval | Not eval | Not eval | − | − |
| II.2 | −4.3 | 4 | 70 | Not eval | + | − |
| II.4 | −5.4 | 2.2/2.2 | 78 | Not eval | + | − |
| II.6 | −3 | 1.5/0.5 | 58 | Not eval, normal breast feeding | + | − |
| II.8 | −4.7 | 2 | 94 | Not eval | + | − |
| II.10 | −4 | 3/0.5 | 10.7 | Not eval, normal breast feeding | + | − |
| III.1 | −3.5 | 4.3/3.1 | 10.4 | 3.1 (12.5/TRH) | + | AP hypo |
| III.4 | −3 | 2.4/2.3 | 15.2 | 5.1 (16.7/TRH) | + | AP hypo |
| III.7 | −3.2 | 2/3.1 | 11.9 | 0.9 (4.6/TRH) | + | N |
Height SD, height standard deviation; GH µg/l: arginine/ornithine tests, normal value >10 µg/l; total T4 ng/ml: normal value 40–120 for II.2, II.4, II.6 and II.8 and free T4 pmol/l (in italic) normal value 10–21 for II.10, III.1, III.4 and III.7; PRL ng/ml, PRL before and after TRH stimulation (between brackets): normal value 2.5–20; Not eval: not evaluated; AP hypo: hypoplasia of the anterior pituitary; N: normal.